Shirisha Pasula
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shirisha Pasula has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Pranatharthi Haran Chandrasekar
Division of Infectious Diseases, Karmanos Cancer Center, Wayne State University School of Medicine , Detroit, Michigan
2 shared publications Almira Opardija
Division of Infectious Diseases, Department of Internal Medicine, University of California, San Francisco, Fresno, California, USA
1 shared publication- Elise Hyser
Division of Infectious Diseases, Department of Medicine, UCSF Fresno, USA
1 shared publication Elvisa Loshe
Department of Ophthalmology, Kresge Eye Institute, Wayne State University, Detroit, USA, MI
1 shared publication- Kian Yazdan
College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA
1 shared publication Nancy Dang-Orita
Division of Infectious Diseases, Department of Internal Medicine, University of California, San Francisco, Fresno, California, USA
1 shared publication
Latest Publications
- Open Access
- 21 August 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (8) , 1861
Fungal Infections Associated with Sphingosine 1-Phosphate Receptor Modulators: Immunological Mechanisms, Clinical Patterns, and Management Considerations
Fungal infections constitute a large portion of serious infections worldwide and are increasing, partially due to new immunomodulatory therapies, such as Sphingosine-1-Phosphate (S1P) receptor modulators, including fingolimod for the treatment of multiple sclerosis (MS). Fingolimod antagonizes multiple S1P receptors, including S1PR1, S1PR3, S1PR4, and S1PR5, resulting in immunological alterations that may increase susceptibility to invasive fungal infections (IFIs). Our PubMed-based literature search identified 43 published cases and a 60-patient case series describing invasive fungal infections in patients receiving S1P receptor modulators. Of these, cryptococcosis was the most frequently documented infection, followed by histoplasmosis and coccidioidomycosis. Most published cases involved patients on fingolimod, whereas evidence for the other medications in this class is extremely limited. Currently, there are no standardized fungal screening protocols. A baseline complete blood count with differentials should be obtained before the initiation of S1P receptor modulator therapy. Patients should also be monitored clinically for signs and symptoms of fungal infection. Primary antifungal prophylaxis and routine serum cryptococcal antigen testing are not currently recommended. Management of suspected IFIs should focus on diagnostic workup to identify the causative organism and extent of organ involvement to determine the appropriate antifungal therapy. Decisions regarding interruption or discontinuation of MS therapy should be individualized according to the clinical syndrome, infection severity, and risk of MS rebound. This narrative review synthesizes the available mechanistic and clinical evidence on invasive fungal infections in patients with multiple sclerosis receiving S1P receptor modulator therapy.
- 21 August 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (8) , 1861
Open AccessFungal Infections Associated with Sphingosine 1-Phosphate Receptor Modulators: Immunological Mechanisms, Clinical Patterns, and Management Considerations
Fungal infections constitute a large portion of serious infections worldwide and are increasing, partially due to new immunomodulatory therapies, such as Sphingosine-1-Phosphate (S1P) receptor modulators, including fingolimod for the treatment of multiple sclerosis (MS). Fingolimod antagonizes multiple S1P receptors, including S1PR1, S1PR3, S1PR4, and S1PR5, resulting in immunological alterations that may increase susceptibility to invasive fungal infections (IFIs). Our PubMed-based literature search identified 43 published cases and a 60-patient case series describing invasive fungal infections in patients receiving S1P receptor modulators. Of these, cryptococcosis was the most frequently documented infection, followed by histoplasmosis and coccidioidomycosis. Most published cases involved patients on fingolimod, whereas evidence for the other medications in this class is extremely limited. Currently, there are no standardized fungal screening protocols. A baseline complete blood count with differentials should be obtained before the initiation of S1P receptor modulator therapy. Patients should also be monitored clinically for signs and symptoms of fungal infection. Primary antifungal prophylaxis and routine serum cryptococcal antigen testing are not currently recommended. Management of suspected IFIs should focus on diagnostic workup to identify the causative organism and extent of organ involvement to determine the appropriate antifungal therapy. Decisions regarding interruption or discontinuation of MS therapy should be individualized according to the clinical syndrome, infection severity, and risk of MS rebound. This narrative review synthesizes the available mechanistic and clinical evidence on invasive fungal infections in patients with multiple sclerosis receiving S1P receptor modulator therapy.
- Open Access
- 6 April 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 167, 108692
Disseminated mucocutaneous leishmaniasis in a patient with advanced HIV
- 6 April 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 167, 108692
Open AccessDisseminated mucocutaneous leishmaniasis in a patient with advanced HIV
- Open Access
- 22 January 2026
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 51, 100761
Mixed mycotic infection in an immunocompromised host with advanced HIV diagnosed with the assistance of a Karius test
- 22 January 2026
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 51, 100761
Open AccessMixed mycotic infection in an immunocompromised host with advanced HIV diagnosed with the assistance of a Karius test
- 21 June 2021
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 22 (15) , 2071-2078
Azole resistance in Aspergillus species: promising therapeutic options
Azoles are the first-line antifungal agents used for the treatment of Aspergillus infection. There is an increasing concern for azole resistance all over the world mainly from agricultural fungicid...
- 21 June 2021
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 22 (15) , 2071-2078
Azole resistance in Aspergillus species: promising therapeutic options
Azoles are the first-line antifungal agents used for the treatment of Aspergillus infection. There is an increasing concern for azole resistance all over the world mainly from agricultural fungicid...
- Open Access
- 21 January 2021
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 22, e929116-e929116-6
Serratia marcescens Infection-Associated Loss of Vision: A Case Report in a Patient with a History of Intravenous Drug Use
Serratia marcescens Infection-Associated Loss of Vision: A Case Report in a Patient with a History of Intravenous Drug Use - Article abstract #929116
- 21 January 2021
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 22, e929116-e929116-6
Open AccessSerratia marcescens Infection-Associated Loss of Vision: A Case Report in a Patient with a History of Intravenous Drug Use
Serratia marcescens Infection-Associated Loss of Vision: A Case Report in a Patient with a History of Intravenous Drug Use - Article abstract #929116